Japanese Journal of Gastroenterology and Hepatology

Creative Review

ISSN: 2435-1210 | Volume 9

Peptide-Based mRNA Vaccines

Farshi E*

Anahita Company, San Diego, California, Medical Research Center, The University of Tennessee, Knoxville, USA

***Corresponding author:**

Esmaeil Farshi,

Medical Research Center, the University of Tennessee, Knoxville, USA, E-mail: farshi@technologist.com and farshiesmaeil@gmail.com

Received: 20 Jan 2023

Accepted: 15 Feb 2023

Published: 22 Feb 2023

J Short Name: JJGH

Citation:

Farshi E. Peptide-Based mRNA Vaccines. J Gastro Hepato. 2023; V9(16): 1-6

Keywords:

Cancer-associated antigen; SARS-Cov-2 virus; mRN

1. Abstract

Peptide-based mRNA vaccines are a novel approach to vaccination that have gained attention as an alternative strategy for certain viral and bacterial pathogens, as well as for cancer immunotherapy. These vaccines have several advantages, such as the ability to quickly and easily design new vaccines in response to emerging pathogens, as well as the potential for targeting multiple antigens in a single vaccine. mRNA, or messenger RNA, is a molecule that carries genetic information from DNA to the ribosome, where it is used to synthesize proteins. Peptide-based mRNA vaccines are designed to target specific peptides, or small pieces of proteins, that are derived from a pathogen or cancer-associated antigen (TAA). This paper studies the current state of research on peptide-based mRNA vaccines, including studies on influenza virus, SARS-Cov-2 virus, and cancer immunotherapy. The studies have shown promising results in eliciting an immune response and reducing the size of tumors in animal models. However, it is important to note that this area of research is still in its early stages and further studies and clinical trials are needed to fully evaluate the safety and efficacy of these vaccines.

2. Introduction

mRNA (messenger RNA) is a molecule that carries genetic information from DNA to the ribosome, where it is translated into proteins. The use of mRNA in vaccines is a relatively new strategy that has been shown to be highly effective in triggering an immune response against viral and bacterial pathogens. One type of mRNA vaccine that is currently being explored is the peptide-based mRNA vaccine. This type of vaccine uses small fragments of viral or bacterial proteins, called peptides, to induce an immune response.

Peptide-based mRNA vaccines are a novel approach to vaccination that have gained attention as an alternative strategy for certain viral and bacterial pathogens, as well as for cancer immunotherapy. mRNA, or messenger RNA, is a molecule that carries genetic information from DNA to the ribosome, where it is used to synthesize proteins. Peptide-based mRNA vaccines are designed to target specific peptides, or small pieces of proteins, that are derived from a pathogen or cancer-associated antigen (TAA). These vaccines have several advantages, such as the ability to quickly and easily design new vaccines in response to emerging pathogens, as well as the potential for targeting multiple antigens in a single vaccine [1].

One of the main advantages of peptide-based mRNA vaccines is their ability to rapidly respond to emerging pathogens. Traditional vaccine development can take several years, but with mRNA vaccines, the genetic sequence of the pathogen can be quickly identified and the mRNA can be synthesized and incorporated into the vaccine. This allows for a faster response to new outbreaks, such as the current COVID-19 pandemic, where mRNA vaccines have been developed and authorized for emergency use in a relatively short period of time.

Another advantage of peptide-based mRNA vaccines is the potential for targeting multiple antigens in a single vaccine. In traditional vaccines, a single antigen is typically targeted, but with mRNA vaccines, multiple antigens can be encoded in the same mRNA molecule. This allows for a more comprehensive immune response and the potential for more effective protection against the pathogen.

In addition to their potential for responding to emerging pathogens, peptide-based mRNA vaccines are also being studied as a potential strategy for cancer immunotherapy. Cancer- associated antigens (TAAs) are proteins that are overexpressed in cancer cells, making them potential targets for the immune system. Peptide-based mRNA vaccines can be designed to target specific TAAs, and have shown promising results in animal models in reducing the size of tumors.

Despite the potential advantages, it is important to note that this area of research is still in its early stages and further studies and clinical trials are needed to fully evaluate the safety and efficacy of these vaccines. In this paper, we will review the current state of research on peptide- based mRNA vaccines, including studies on influenza virus and cancer immunotherapy. We will also discuss the challenges and limitations of this approach and the future directions for research in this field.

3. What's mRNA?

mRNA (messenger RNA) is a type of RNA that carries genetic information from DNA to the ribosome, where it is translated into proteins [2]. The process of protein synthesis, also known as translation, is vital for the growth and function of cells. mRNA plays a central role in this process by providing the instructions for the synthesis of specific proteins.

mRNA is synthesized in the nucleus of the cell, where it is transcribed from DNA. The process of transcription is carried out by enzymes called RNA polymerases, which read the DNA code and produce a complementary RNA molecule. The mRNA molecule then exits the nucleus and travels to the cytoplasm, where it binds to ribosomes.

Ribosomes are complex molecular machines that read the sequence of nucleotides in the mRNA and translate it into a sequence of amino acids in a protein. The sequence of nucleotides in the mRNA is read in groups of three, called codons, with each codon specifying a specific amino acid. The process of translation is highly regulated, with multiple mechanisms in place to ensure the correct translation of mRNA into protein.

Once the protein is synthesized, it can perform a wide range of functions, such as catalyzing reactions, transporting molecules, and providing structural support. The protein can also be modified after synthesis, including modification of the amino acids, folding into specific 3D structure, and finally targeting to specific cellular location where it can perform its function.

In summary, mRNA plays a crucial role in the process of protein synthesis by providing the instructions for the synthesis of specific proteins. This process is vital for the growth and function of cells, and the regulation of mRNA is critical for the proper functioning of cells (Figure 1 and 2).



Figure 1: DNA and mRNA



Figure 2: Amino Acids, Peptide, Protein

4. mRNA Vaccines

mRNA vaccines are a new type of vaccine that have been developed in recent years as an alternative to traditional vaccines [3]. These vaccines work by introducing a small piece of genetic material, called messenger RNA (mRNA), into the body. The mRNA provides the instructions for the body's cells to produce a specific protein, which then triggers an immune response. This immune response helps protect against future infections with the same virus or bacteria.

Currently, there are several mRNA vaccines that have been developed and authorized for emergency use, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, which use mRNA to instruct cells to produce a spike protein found on the surface of the SARS-CoV-2 virus, thus triggering an immune response that can protect against COVID-19. Additionally, there are other mRNA vaccines in development for different pathogens such as flu, Zika, and cancer. The unique feature of mRNA vaccines is that they can be developed and manufactured quickly, as the mRNA does not need to be grown inside living cells and can be synthesized in a laboratory (Figure 3 and 4).



Figure 3: mRNA vaccine for cancer immunotherapy



Figure 4: COVID-19 mRNA vaccine

5. Peptide-based mRNA Vaccines

Peptide-based mRNA vaccines are a novel approach to vaccination that utilizes mRNA to encode for specific peptides rather than full proteins [4]. Traditional mRNA vaccines, such as those developed for COVID-19, use mRNA to encode for a full viral protein, such as the spike protein of SARS-CoV-2. Peptide-based mRNA vaccines, on the other hand, use mRNA to encode for specific peptides derived from a viral or bacterial protein.

One of the main advantages of peptide-based mRNA vaccines is their ability to target specific epitopes, or regions of a protein that are recognized by the immune system. By focusing on specific epitopes, peptide-based mRNA vaccines can potentially elicit a stronger and more specific immune response compared to traditional mRNA vaccines.

Another advantage of peptide-based mRNA vaccines is their ability to target multiple epitopes from a single protein. For example, in the case of the spike protein of SARS-CoV-2, multiple peptides may be obtained, each of which targets a different epitope. This allows for the possibility of a broader immune response, covering multiple areas of the spike protein.

In addition, peptide-based mRNA vaccines have the potential to be used in the treatment of cancer, as they can target specific Tumor-Associated Antigens (TAAs) found on the surface of cancer cells. Studies have been conducted using peptide-based mRNA vaccines to target TAAs such as MUC1 and HER2, with promising results in preclinical models.

While peptide-based mRNA vaccines have several advantages, they are currently still in the research phase and have yet to be approved for human use. Further studies are needed to evaluate their safety and efficacy before they can be used in clinical practice.

In summary, peptide-based mRNA vaccines are a promising new approach to vaccination that utilizes mRNA to encode for specific peptides, rather than full proteins. These vaccines have the potential to elicit a stronger and more specific immune response, target multiple epitopes from a single protein, and be used in the treatment of cancer, but more research is needed before they can be used in clinical practice.

6. Peptide-Based mRNA Vaccines for Cancer Treatment

Peptide-based mRNA vaccines for cancer treatment is a novel approach that aims to harness the power of the immune system to target and destroy cancer cells. This approach utilizes mRNA to encode for specific peptides derived from cancer-associated proteins, which are then used to stimulate an immune response against the cancer cells.

Peptide-based mRNA vaccines work by delivering mRNA into the body, where it is taken up by cells and used as a blueprint to produce the target peptides. These target peptides are derived from cancer cells and are chosen because they are unique to the cancer cells and not present on normal cells.

Once produced, the target peptides are displayed on the surface of the cells, serving as a flag for the immune system to recognize and attack. The immune system is designed to identify and destroy cells that display abnormal or foreign substances, and the display of the target peptides on the cell surface triggers the immune system to attack the cancer cells.

In addition to eliciting an immune response against the cancer cells, peptide-based mRNA vaccines also have the potential to stimulate the body's own immune system to produce long- lasting memory cells that recognize and remember the cancer cells. This means that if the cancer cells return, the immune system is ready and able to attack them again.

This mechanism of action is different from traditional cancer treatments, such as chemotherapy and radiation, which directly attack and kill cancer cells, often with harmful side effects. Peptide- based mRNA vaccines offer a more targeted approach that harnesses the body's own immune system to fight the cancer, potentially leading to fewer side effects and a more effective treatment.

There is potential of a peptide-based mRNA vaccine for the treatment of melanoma [5]. Melanoma is a type of skin cancer that can spread to other parts of the body and can be difficult to treat once it has spread. A peptide-based mRNA vaccine that encoded for a specific peptide derived from a protein expressed on the surface of melanoma cells. Such vaccine may be designed to target the melanoma cells and stimulate an immune response against them. The results showed that the vaccine was able to stimulate an immune response against melanoma cells in animal models, including the production of specific immune cells known as T-cells and the activation of these T-cells against the melanoma cells. The results suggest that the peptide- based mRNA vaccine has the potential to be a promising new approach to melanoma treatment. However, it is important to note that this was a preclinical study in animal models and further research is needed to determine its efficacy and safety in humans.

There is potential to use a peptide-based mRNA vaccine for the treatment of pancreatic cancer [6]. Pancreatic cancer is a particularly aggressive and difficult to treat form of cancer, with a low survival rate. It may be used a peptide-based mRNA vaccine that encoded for a specific peptide derived from a protein expressed on the surface of pancreatic cancer cells. The vaccine was designed to target the cancer cells and stimulate an immune response against them. The results have showed that the vaccine was able to stimulate an immune response against pancreatic cancer cells in animal models, including the activation of specific immune cells known as T-cells against the cancer cells. Additionally, the vaccine was found to have a therapeutic effect, reducing the size of the pancreatic tumors in the animal models.

The studies show the potential of a peptide-based mRNA vaccine for the treatment of ovarian cancer [7]. The vaccine was designed to target specific epitopes on ovarian cancer cells, using mRNA to encode for specific peptides derived from cancer proteins. The results showed that the vaccine was able to elicit an immune response against ovarian cancer cells in animal models.

This response was characterized by the activation and recruitment of immune cells, such as T- cells, to the site of the cancer cells. These immune cells then attacked and destroyed the cancer cells, demonstrating the potential of the peptide-based mRNA vaccine to effectively target and treat ovarian cancer. The study provides further evidence of the potential of peptide-based mRNA vaccines as a new approach to cancer treatment. By targeting specific epitopes on cancer cells, these vaccines can elicit a strong and specific immune response against the cancer cells, providing a promising new option for patients with ovarian cancer and other types of cancer.

It may be used peptide-based mRNA vaccine as a potential treatment for lung cancer [8]. The vaccine consisted of mRNA encoding for specific peptides derived from lung cancer cells. When administered to animal models, the vaccine was able to stimulate an immune response against the cancer cells, which led to the destruction of cancer cells and the reduction of tumor growth. The mechanism of action of the vaccine involved the delivery of mRNA into the body, where it was taken up by cells and used as a blueprint to produce the target peptides. These peptides were then presented on the surface of cells, serving as a flag for the immune system to recognize and attack the cancer cells. The results showed that the peptide-based mRNA vaccine was able to elicit an immune response against lung cancer cells in animal models, providing promising evidence for its potential as a new approach to lung cancer treatment. Further studies in larger animal models and eventually in human clinical trials would be needed to fully evaluate the safety and efficacy of this approach.

Peptide-based mRNA vaccines for the treatment of breast cancer involve the delivery of mRNA encoding for specific peptides derived from cancer cells into the body [9]. Once inside the body, the mRNA is taken up by cells and used as a blueprint to produce the target peptides. These peptides are then displayed on the surface of the cells, which serves as a flag for the immune system to recognize and attack the cancer cells. Studies have been conducted to evaluate the potential of peptide-based mRNA vaccines for the treatment of breast cancer, with promising results. One suggestion is a peptide-based mRNA vaccine encoding for multiple peptides derived from breast cancer cells was able to elicit a potent immune response against the cancer cells in animal models. The results suggest that this approach may be a promising new way to treat breast cancer and further research is needed to determine its safety and efficacy in humans.

In reference 12, the idea of using mRNA vaccine for SARS-Cov-2 has been discussed.

7. Peptide-Based mRNA Vaccines for SARS-CoV-2

Peptide-based mRNA vaccines represent a promising new approach to vaccination against SARS-CoV-2, the virus that causes COVID-19.

The mechanism of action of peptide-based mRNA vaccines involves the delivery of mRNA into the body, where it is taken up by cells and used as a blueprint to produce the target peptides.

These peptides, derived from the spike protein of SARS-CoV-2, are then presented on the surface of the cells, which serves as a flag for the immune system to recognize and attack the virus.

The mRNA provides the cells with the necessary information to produce the target peptides, which are then displayed on the surface of the cells in a way that can be recognized by the immune system. The immune system, in turn, mounts a response against the peptides, and as a result, the virus. This response can include the production of specific antibodies and the activation of T cells, both of which can play important roles in preventing or clearing the virus.

The advantage of this approach is that it allows for the creation of vaccines that target specific epitopes on the virus, which can increase the potency and specificity of the immune response. This can lead to better protection against the virus and a reduced risk of side effects compared to traditional vaccines.

Overall, the mechanism of action of peptide-based mRNA vaccines provides a new and innovative approach to vaccination that has the potential to be a powerful tool in the fight against SARS-CoV-2 and COVID-19.

Then generally the mechanism of action of the peptide-based mRNA vaccine for SARS-CoV-2 is based on delivering mRNA into the body, which contains the genetic code for the production of the target peptides. These peptides are then produced within the body and presented on the surface of cells, acting as a flag for the immune system to recognize and attack.

In one study, the vaccine encoded for multiple peptides derived from the spike protein of SARS- CoV-2 [10]. The spike protein is a key target for the immune system as it is present on the surface of the virus and is essential for its infectivity. By delivering mRNA containing the code for multiple peptides from the spike protein, the vaccine aimed to elicit a potent immune response against the virus. The results showed that the vaccine was able to stimulate the production of SARS-CoV-2-specific antibodies and activate T cells, a type of immune cell that is critical for recognizing and destroying infected cells. This suggests that the vaccine was able to generate a strong immune response against the virus in animal models, providing evidence for its potential as a new approach to vaccination against SARS-CoV-2.

Another study showed the potential of a peptide-based mRNA vaccine encoding for a specific peptide derived from the spike protein [11]. The results showed that the vaccine was able to elicit a potent immune response in animal models, including the production of SARS-CoV-2-specific antibodies and activation of T cells. This study aimed to evaluate the potential of a peptide-based mRNA vaccine encoding for a specific peptide derived from the spike protein of SARS-CoV-2. The spike protein is a critical target of the immune response as it is the protein that allows the virus to enter host cells. The study was conducted in animal models and found that the vaccine was able to elicit a potent immune response against SARS-CoV-2.

This included the production of specific antibodies against the virus and activation of T cells, which are critical components of the immune response against the virus. These results demonstrate the potential of peptide-based mRNA vaccines as a new approach to vaccination against SARS-CoV-2. By targeting specific peptides on the virus, these vaccines have the potential to provide a more effective immune response compared to traditional vaccines. However, it is important to note that these studies were conducted in animal models and further research, including clinical trials in humans, is needed to determine the efficacy and safety of these vaccines in humans.

In reference [12] a peptide-based mRNA vaccine for SARS-CoV-2 that has been described that uses engineered peptides to bind to the spike protein of the virus and trigger an immune response. The mRNA encoding for a stable form of the spike protein is used to activate T cells, which provide long-term immunity against the virus. This vaccine is a new and innovative approach to vaccination that does not require growing the virus in the laboratory and is based on a relatively new genetic method. The results of the study showed that the vaccine was effective in animal models, as monkeys given the vaccine were able to fight off the virus. Additionally, the study found that the vaccine was able to elicit a potent immune response, including the production of SARS-CoV-2-specific antibodies and activation of T cells. The activation of T cells is especially important because it provides long-term immunity against the virus, as memory T cells remain in the body for at least 11 years. This is in contrast to traditional vaccines that may only provide short-term protection through the production of antibodies.

The use of mRNA technology in the vaccine allows it to bypass the need to grow the virus in the laboratory, making it a safer and more efficient alternative. The mRNA encoding for the spike protein is delivered to the body, where it is processed by immune cells and used to synthesize specific viral protein antigens. These antigens are then recognized by other immune cells, triggering an immune response against the virus.

It is important to note that while the results of the study are promising, more research is needed to determine the efficacy and safety of the vaccine in humans. Nevertheless, the results suggest that the peptide-based mRNA vaccine has the potential to be a powerful tool in the fight against COVID-19, providing a new and innovative approach to vaccination.

8. Conclusion

In conclusion, the mRNA vaccines have shown promising results not only in the fight against COVID-19 but also in the field of cancer treatment. Peptide-based mRNA vaccines work by delivering mRNA encoding specific peptides derived from cancer cells into the body, triggering an immune response against the cancer cells. The approach has shown potential in treating various types of cancer, including melanoma, pancreatic cancer, ovarian cancer, lung cancer, and breast cancer. However, further research is necessary to fully evaluate the safety and efficacy of this approach in human clinical trials.

Despite this, the results from animal studies have been encouraging, indicating that mRNA vaccines may have a role in the future of cancer treatment. This new technology holds great promise in the fight against cancer and represents a significant step forward in personalized medicine, where treatment is tailored to the specific needs of each individual patient. In addition to the potential use in cancer treatment, mRNA vaccines have also shown their effectiveness in preventing and controlling infectious diseases, such as COVID-19. This highlights the versatility of mRNA technology and its potential to revolutionize the way we approach healthcare in the future. In conclusion, mRNA vaccines are a promising new technology with potential applications in both the prevention and treatment of diseases, and further research and development is needed to fully realize their potential.

References

1. Rezaei M, Nazari M. New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA. Avicenna J Med Biotechnol. 2022; 14(1): 30-6.
2. Bustin SA. INVITED REVIEW Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. Journal of molecular endocrinology. 2002; 29: 23-39.
3. Pardi, Norbert, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery. 2018; 17(4): 261-79.
4. Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Molecular Cancer. 2021; 20(1): 33.
5. Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines. 2021; 9: 1060.
6. Chen Z, Zhang S, Han N, Jiang J, Xu Y, Ma D, et al. A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment. Frontiers in Immunology. 2021; 12: 691605.
7. Nicolás-Morales ML, Luisa-Sanjuan A, Gutiérrez-Torres M, Vences-Velázquez A, Ortuño-Pineda C, Espinoza-Rojo M, et al. Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review. Vaccines. 2022; 10(8): 1249.
8. García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines. 2022; 10(5): 740.
9. Abbaspour M, Akbari V. Cancer vaccines as a targeted immunotherapy approach for breast cancer: An update of clinical evidence. Expert Review of Vaccines. 2022; 21(3): 337-53.
10. Lim HX, Lim J, Jazayeri SD, Poppema S, Poh CL. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomedical Journal. 2021; 44(1): 18-30.
11. Shalash AO, Hussein WM, Skwarczynski M, Toth I. Key considerations for the development of safe and effective SARS-CoV-2 subunit vaccine: A peptide-based vaccine alternative. Advanced Science. 2021; 8(16): 2100985.

12. Farshi, E. Immunological Reason for Mild Affection of Children to COVID-19, A Key Factor for Novel Solution of Vaccination and Medications. Japanese J Gstro Hepato. 2021; 8(2): 1-9.

13. Farshi E. Peptide-mRNFarshi Vaccine for SARS-Cov-2. J Vaccines Vaccin. 2020; 11: 431.